MP Advisors Market Research Reports

TITLE Actions
Next Decade Generic String Of Pearls Opportunities: Sustainability Assessment With Respect To Therapeutic Positioning
Published in Nov 2017 | US $ 4000 Onwards | By MP Advisors

The rapid growth of the generic industry has come with a number of challenges, such as heavy competition, including from authorized generics and government-mandated price cuts. All contribute to diminishing prices and ever decreasing margins. In t...

The Future of the U.S. Biologics and Biosimilars Treatment Market for Psoriasis
Published in Oct 2017 | US $ 4000 Onwards | By MP Advisors

The U.S. psoriasis treatment market for Biologics and Biosimilars was estimated at $6.6bn in 2016 is projected to almost double during the forecast period to reach $12.9bn in 2021 driven by safety and efficacy improvements of the new generation bi...

Japan Biosimilars – A start of Authorized Biosimilar Era? Biosimilar/BioPharma CMO opportunities – JP Conglomerates – A definite role to play for Global Market! Major JP Innovator vs. Early entrant Mid size Japanese companies- TA focus approach – A Win Win Game!
Published in Aug 2017 | US $ 4000 Onwards | By MP Advisors

In 2016, encouraging uptake of Lantus BS in Japan confirms strong foothold of the marketer, product mix targeted to DPC hospitals (Diagnostic Procedure Combination hospitals- ~4000) and early entry of the player are critical factors to decide bios...

Prostate Cancer - Newer Antiandrogens & Emerging Therapies Targeting a “Watchful Waiting” and Resistance Population
Published in Feb 2017 | US $ 4500 Onwards | By MP Advisors

Xtandi – Replacing competitor from Zytiga to Casodex (Bicalutamide) for a  bigger pie in Prostate cancer & Finding its niche in crowded BC market Xtandi + Zytiga vs.  ARN-509 + Zytiga   -   Who will win the ...

Pain Management- New Discoveries And Treatment Options In Abuse Deterrent Era
Published in Sep 2016 | US $ 3500 Onwards | By MP Advisors

Rescheduling of Hydrocodone combinations from Class III to Class II, clear-cut regulatory guideline for Abuse Deterrent drug formulation NDA & ANDA (solid oral) filing and CDC guideline for Prescribing Opioids for Chr...

India Pharma Outlook 2016: Milestones to Watch – Growth from Exports and Domestic Getting Better, Implementation of Policies under “Make-in-India”, Overture of A New Ministry
Published in Mar 2016 | US $ 1500 Onwards | By MP Advisors

2016 will be a crucial for drug makers and consumers. During ?Make-in-India' week in Mumbai, Govt. highlighted many amendments or introduction of new policies with an aim to make India as a major hub for end to end drug discovery. To boost drug di...

Large Cap Pharma US & EU Outlook 2016: Maximizing Their Strength On Fewer Therapy Class, Personalized Medicine, Novel Target And Biosimilars For Future Growth
Published in Mar 2016 | US $ 2000 Onwards | By MP Advisors

Major pharma companies are continue to improve the productivity by taking different approaches like focusing on selected therapy area and markets, merger and acquisition, divestment of non-core brands/segments and consolidation in animal health, v...

Japan Pharma Outlook 2016 : JP Giants leaning in for becoming a Speciality Global Pharma
Published in Mar 2016 | US $ 2500 Onwards | By MP Advisors

Sakigake designation - A Push from government to "Innovate"!"Essential drugs" exemption from Z2 rule- Balancing long listed pricing pressure!Authorized Generics, Biosimilars, and Patent Litigations - Avenues to gr...

Rising Stars Outlook 2016 :New Emergence of Potential Tx & Dx Options could transform the Current Landscape for Liver Diseases (NASH)
Published in Jan 2016 | US $ 2000 Onwards | By MP Advisors

Non-Alcoholic SteatoHepatitis (NASH) is an unmet medical need and is becoming the leading cause of liver transplant. No FDA-approved therapies and a meager diagnosis, it poses a unique challenge in the design of studies for NASH. Therefore, there ...

Non-Alcoholic SteatoHepatitis (NASH): An Analysis of Disease Prevalence, Drugs in development, Regulatory guidelines and Market opportunity in Various Geographies
Published in Dec 2015 | US $ 3500 Onwards | By MP Advisors

Sales of Hepatitis C drugs crossed ~$10bn in 2014 proving that treatments for liver disease could become mega-blockbusters and Non-Alcoholic SteatoHepatitis (NASH) is expected to be equally lucrative.  Improved diagnosis rate and change in tr...

Japan Biosimilar- Active Players In Quest of a Specialty & Niche BS space
Published in Dec 2015 | US $ 4000 Onwards | By MP Advisors

Filgrastim BS and Lantus BS Approval- Encouraging uptake and a lesson to fast track JP approval based on Ex-Japan data!Remicade biosimilar “NK” – A slow start does not pull back NK in starting PhIII for Herceptin BS in Jap...

BUCCAL DRUG DELIVERY SYSTEMS: OPPORTUNITIES AND CHALLENGES IN BUCCAL, SUBLINGUAL FILMS, TABLETS & SPRAYS - Detailed analysis on Technologies and Pipeline Development
Published in Oct 2015 | US $ 3000 Onwards | By MP Advisors

Within the oral mucosal cavity, the buccal region offers an attractive route of administration for systemic drug delivery. The mucosa has a rich blood supply and it is relatively permeable.  The buccal mucosa offers several advantages for con...

India Pharma Outlook 2015: Accelerating growth to the next level: Moving up the value chain beyond Generics
Published in Feb 2015 | US $ 2000 Onwards | By MP Advisors

Domestic sales improved in 2014, recovering from the slump in the 2013 caused by the market's reaction to the new drug pricing policy. In 2015, growth is expected to continue to be healthy, as the momentum continues and improving economic grow...

Japan Pharma Outlook 2015: 2015 –Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives
Published in Jan 2015 | US $ 2000 Onwards | By MP Advisors

The new pricing system adopted in Japan from April -2014 (Annexure 1) is a game changer initiative. It pains most of the companies - whether generic or innovator. The most of the companies are revalidating their domestic (and thus overseas) strate...

Sri Lanka Pharma Market Outlook 2015: More beyond Importers & Distributors
Published in Jan 2015 | US $ 2000 Onwards | By MP Advisors

With the recent development, Sri Lanka's aim of developing a pharma industry should be to penetrate the global market since the internal market is not sufficient for any big firm to operate at optimum levels. According to a report published by...

Global Pharma US & EU Outlook 2015 : First –In- Class Innovations and Cost Optimization Plays Major Role In Shaping Up Business for Large Cap Pharmaceutical Companies
Published in Jan 2015 | US $ 2000 Onwards | By MP Advisors

Strategy Diversification Divested: Productivity measurements, Divestment of non-core assets resulting in healthy Cash position- Will accelerate Next wave of targeted acquisition. In the recent years several new therapies have been approved...

Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success
Published in Jan 2015 | US $ 2000 Onwards | By MP Advisors

All biotech companies - Gilead (GILD), Amgen (AMGN), Biogen Idec (BIIB) and Celgene (CELG), in past year, have given a positive return and hence increased the interest of biotech investors. These companies have been able to select therapy/niche in...

Hematological Malignancies: Multiple Myeloma (MM) – Early and Robust Diagnosis along with New Treatment Options can have Considerable Impact on Management of the Disease
Published in Jan 2015 | US $ 3000 Onwards | By MP Advisors

While targeting unmet needs in the treatment of hematological malignancies/ cancer through innovative drug development strategies have witnessed favorable outcomes, the specific choice of the therapies is dependent on the identification of importa...

Global Rising Stars Outlook 2015: Innovative Therapies for treating diseases are being sought after with fresh vigor as new targets.
Published in Jan 2015 | US $ 2000 Onwards | By MP Advisors

Innovative Therapies for treating diseases are being sought after with fresh vigor as new targets , approaches and biology is discovered. One field which is poised to bring a paradigm change in the way diseases are treated in the next decades is t...

Dietary Supplements: World of Opportunities In the Indian Healthcare Market
Published in Jan 2015 | US $ 2000 Onwards | By MP Advisors

Increasing rate of chronic diseases has emphasized the need of Prevention over Intervention.  These proactive health solutions include nutritional supplements which promise medical or health benefits and fall between the food and pharma chain...

We are on:

Need Help?